There are currently three drugs containing this active ingredient on the market, all of which are manufactured by Novo Nordisk, specifically Ozempic, Wegovy, and Rybelsus

Patient Assessment Protocol Comprehensive medical history with obesity-specific screening Physical examination including BMI, waist circumference, and body composition analysis Laboratory workup: complete metabolic panel, lipid panel, HbA1c, thyroid function, insulin levels Screening for sleep apnea, PCOS, Cushing syndrome, and other secondary causes of obesity Mental health screening for binge eating disorder and depression Readiness-to-change assessment Medication Formulary for Your Medical Weight Loss Program GLP-1 receptor agonists: Semaglutide (Wegovy), liraglutide (Saxenda), tirzepatide (Zepbound) Sympathomimetic agents: Phentermine (short-term), phentermine/topiramate (Qsymia) Other FDA-approved options: Naltrexone/bupropion (Contrave), orlistat (Xenical/Alli) Off-label considerations: Metformin, topiramate, bupropion (when clinically appropriate and properly documented) Your medical weight loss program's protocols should specify prescribing criteria, dosing escalation schedules, monitoring requirements, and discontinuation criteria for each medication

approved outside U.S.)
The Express Scripts form plays a vital role in this process, ensuring that medications are dispensed accurately and in a timely manner
Effects of sub-chronic DDT exposure on humoral and cell-mediated immune responses in albino rats